Tiziana Life Sciences (TLSA) vs Yarrow Bioscience (YARW)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Yarrow Bioscience (YARW) has outperformed Tiziana Life Sciences (TLSA) over the past year, losing 4.6% versus a loss of 44.1%. Over five years, TLSA leads with a -21.2% price change compared with -98.2% for YARW. Yarrow Bioscience is the larger company by market cap ($183.4 million vs $151.4 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | TLSA | YARW |
|---|---|---|
| Share price | $1.19 | $19.71 |
| Market cap | $151.44M | $183.39M |
| 1-day change | +5.31% | -0.81% |
| YTD return | -20.13% | -32.03% |
| 1-year return | -44.13% | -4.55% |
| 5-year return | -21.19% | -98.20% |
| EPS (TTM) | $-0.16 | — |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.25 | $46.95 |
| 52-week low | $0.76 | $16.05 |
| Distance from 52-week high | -47.11% | -58.02% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +572.27% | +189.19% |
| Average volume | 720.16K | 85.28K |
| Shares outstanding | 127.26M | 9.30M |
| Employees | 10 | 7 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- YARW has outperformed TLSA by 39.6 percentage points over the past year.
About Tiziana Life Sciences
TLSA stock →Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer's disease, multi system atrophy, and amyotrophic lateral sclerosis; and TZLS-501, a human anti-IL-6R monoclonal antibody for the treatment of autoimmune and inflammatory diseases.
Healthcare · Biotechnology · 10 employees
About Yarrow Bioscience
YARW stock →Yarrow Bioscience, Inc. operates as a clinical-stage biotechnology company that engages in developing transformative therapies for autoimmune thyroid diseases.
Healthcare · Biotechnology · 7 employees
TLSA vs YARW FAQ
Which is bigger, Tiziana Life Sciences or Yarrow Bioscience?
Yarrow Bioscience (YARW) is larger, with a market capitalization of $183.39M compared with $151.44M for Tiziana Life Sciences (TLSA).
Which stock has performed better over the past year, TLSA or YARW?
YARW returned -4.55% over the past 12 months, compared with -44.13% for TLSA (price return, excluding dividends). Past performance does not predict future results.
Are Tiziana Life Sciences and Yarrow Bioscience in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.